FDA’s Top Vaccine Official Resigns, Biotech Stocks Plummet Premarket

Shares of U.S. biotech companies fell as much as 10% in premarket trading on Monday following reports that Dr. Peter Marks, the FDA’s top vaccine regulator, has resigned, effective April 5. Dr. Marks was a key figure during Operation Warp Speed, spearheading the development and approval of COVID-19 vaccines.

According to sources, Dr. Marks cited “misinformation and lies” from Health and Human Services Secretary Robert F. Kennedy Jr. as a contributing factor to his decision to step down. The move has sent ripples through the biotech sector, with investors expressing concern over potential impacts on the pace of future drug approvals.

The Biotechnology Innovation Organization (BIO) warned that Dr. Marks’s departure could undermine scientific standards at the FDA, particularly in an environment already shaken by the administration’s plans to cut 3,500 FDA positions. These proposed staff reductions have further fueled fears that the regulatory review process for innovative therapies may slow down.

As the news spreads, market uncertainty has intensified, with analysts closely watching developments in the FDA and the broader implications for U.S. biotech firms. The resignation of a leading figure like Dr. Marks comes at a critical time for the industry, already navigating a rapidly evolving regulatory landscape.